Table 2.

STAT3 ASO treatment reduces HCCLM3 tumor size, weight, and metastasis

Treatment groupsTumor size
Lung metastasis
Volume (mm3)Weight (g)Cases (%)Metastasis (no.)
Regimen 1
    Saline1,471 ± 3591.73 ± 0.179 of 9 (100)6.2 ± 1.8
    Control oligonucleotide1,311 ± 1311.67 ± 0.278 of 9 (89)6.1 ± 1.8
    STAT3 ASO634 ± 117*0.93 ± 0.12*0 of 9 (0)*0*
Regimen 2
    Saline1,564 ± 2691.89 ± 0.249 of 9 (100)6.8 ± 1.3
    Control oligonucleotide1,372 ± 1521.77 ± 0.399 of 9 (100)6.5 ± 1.5
    STAT3 ASO802 ± 158*1.18 ± 0.11*2 of 9 (22)*2.5 ± 1.1*
  • NOTE: Dissection of intrahepatic tumors and evaluation of lung metastasis in mice was done on day 35 following orthotopic implantation of HCCLM3 tumor fragments and subsequent therapeutic treatment with STAT3 ASO or controls (n = 9 per group). Tumor sizes are presented by both volume in cubic millimeters and weight in grams (mean ± SD). Lung metastasis is denoted as both the positive metastases in the lungs (the percentages are indicated in parentheses) and the average number of metastases (no.) in lungs per positive case (mean ± SD).

  • * P < 0.05.